GoAI
Get started
Crinetics Pharmaceuticals, Inc. logo

Crinetics Pharmaceuticals, Inc.

CRNX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$84.78

+$0.09 · +0.11%

Aug 24, 4:00 PM ET

After-hours

$84.78

$0.00 · 0.00%

Aug 24, 7:30 PM ET

CRNX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

55

Fair Value

Momentum

84

Strong Up

Sentiment

58

Mixed

Risk resilience

68

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
R. Scott Struthers
Listed since
Jul 18, 2018
Employees
594

Market position

Day range

Current $84.78

52-week range

Current $84.78

Open
$84.71
Previous close
$84.69
Volume
1.06M
0.33× average
Average volume
3.17M
Average daily volume
Market cap
8.98B USD
Beta
0.13
Market reference 1
50-day average
$68.847
+23.14% above average
200-day average
$49.1603
+72.46% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.33B USD
P/E (TTM)
-16.79×
P/B (TTM)
7.51×
P/S (TTM)
213.11×
EV / EBITDA
-9.38×
Earnings yield
-10.63%
Free cash flow yield
-8.76%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
99.16%
Operating margin
-1302.52%
Net margin
-1189.88%
Return on equity
-46.90%
Return on assets
-40.98%
Return on invested capital
-48.89%

Financial health

Debt / equity
0.04×
Current ratio
12.32×
Altman Z-score
39.49
Piotroski F-score
2 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends3371%-9714%-22799%-35885%Gross margin, FY2021: 100.00%Gross margin, FY2022: 100.00%Gross margin, FY2023: 100.00%Gross margin, FY2024: 100.00%Gross margin, FY2025: 86.02%Operating margin, FY2021: -9990.91%Operating margin, FY2022: -3544.06%Operating margin, FY2023: -5547.17%Operating margin, FY2024: -32613.47%Operating margin, FY2025: -6714.77%Net margin, FY2021: -9985.25%Net margin, FY2022: -3460.38%Net margin, FY2023: -5345.85%Net margin, FY2024: -28720.69%Net margin, FY2025: -6046.22%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2022 100.00%. Gross margin FY2023 100.00%. Gross margin FY2024 100.00%. Gross margin FY2025 86.02%. Operating margin FY2021 -9990.91%. Operating margin FY2022 -3544.06%. Operating margin FY2023 -5547.17%. Operating margin FY2024 -32613.47%. Operating margin FY2025 -6714.77%. Net margin FY2021 -9985.25%. Net margin FY2022 -3460.38%. Net margin FY2023 -5345.85%. Net margin FY2024 -28720.69%. Net margin FY2025 -6046.22%.

Income trends

Revenue

7.7M USD+640.71%

Operating income

−516.77M USD-52.50%

Net income

−465.32M USD-55.93%
Income trends across reported periods60.14M USD−149.64M USD−359.43M USD−569.22M USDRevenue, FY2021: 1.08M USDRevenue, FY2022: 4.74M USDRevenue, FY2023: 4.01M USDRevenue, FY2024: 1.04M USDRevenue, FY2025: 7.7M USDOperating income, FY2021: −107.7M USDOperating income, FY2022: −167.88M USDOperating income, FY2023: −222.61M USDOperating income, FY2024: −338.85M USDOperating income, FY2025: −516.77M USDNet income, FY2021: −107.64M USDNet income, FY2022: −163.92M USDNet income, FY2023: −214.53M USDNet income, FY2024: −298.41M USDNet income, FY2025: −465.32M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 1.08M USD. Revenue FY2022 4.74M USD. Revenue FY2023 4.01M USD. Revenue FY2024 1.04M USD. Revenue FY2025 7.7M USD. Operating income FY2021 −107.7M USD. Operating income FY2022 −167.88M USD. Operating income FY2023 −222.61M USD. Operating income FY2024 −338.85M USD. Operating income FY2025 −516.77M USD. Net income FY2021 −107.64M USD. Net income FY2022 −163.92M USD. Net income FY2023 −214.53M USD. Net income FY2024 −298.41M USD. Net income FY2025 −465.32M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue7.7M USD1.04M USD4.01M USD4.74M USD1.08M USD
Cost of goods sold1.08M USD————
Gross profit6.62M USD1.04M USD4.01M USD4.74M USD1.08M USD
Research and development332.06M USD240.16M USD168.53M USD130.23M USD84.26M USD
Selling, general, and administrative191.33M USD99.74M USD58.09M USD42.39M USD24.53M USD
Operating expenses523.39M USD339.89M USD226.62M USD172.62M USD108.78M USD
Interest income51.99M USD41.44M USD13.44M USD4.32M USD157K USD
Depreciation and amortization3.89M USD2.79M USD1.1M USD983K USD922K USD
Operating income−516.77M USD−338.85M USD−222.61M USD−167.88M USD−107.7M USD
Net income−465.32M USD−298.41M USD−214.53M USD−163.92M USD−107.64M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
27%
3 beats, 8 misses, 0 met estimates
Average EPS surprise
-3.31%
11 comparable reports
Latest EPS result
-1.14
Estimate -1.18 · Beat by 3.39%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.82-1.03-1.23-1.44Q1 '25BeatQ2 '25MissQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual -0.88, estimate -0.92, surprise +4.35%, Beat. Q2 2025, reported May 8, 2025: actual -1.04, estimate -0.99, surprise -5.05%, Miss. Q3 2025, reported Aug 7, 2025: actual -1.23, estimate -1.13, surprise -8.85%, Miss. Q4 2025, reported Nov 6, 2025: actual -1.38, estimate -1.27, surprise -8.66%, Miss. Q1 2026, reported Feb 26, 2026: actual -1.29, estimate -1.37, surprise +5.84%, Beat. Q2 2026, reported May 7, 2026: actual -1.23, estimate -1.22, surprise -0.82%, Miss. Q3 2026, reported Aug 3, 2026: actual -1.14, estimate -1.18, surprise +3.39%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate -1.2, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates27.12M18.12M9.12M121.55KQ1 '25EstimateQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 27, 2025: actual —, estimate 727.27K USD, surprise —, Comparison unavailable. Q2 2025, reported May 8, 2025: actual 361K USD, estimate 347.91K USD, surprise +3.76%, Beat. Q3 2025, reported Aug 7, 2025: actual 1.03M USD, estimate 394K USD, surprise +161.68%, Beat. Q4 2025, reported Nov 6, 2025: actual 143K USD, estimate 4.32M USD, surprise -96.69%, Miss. Q1 2026, reported Feb 26, 2026: actual 6.16M USD, estimate 4.49M USD, surprise +37.22%, Beat. Q2 2026, reported May 7, 2026: actual 10.73M USD, estimate 8.51M USD, surprise +26.07%, Beat. Q3 2026, reported Aug 3, 2026: actual 25.12M USD, estimate 14.84M USD, surprise +69.24%, Beat. Q4 2026, reported Nov 5, 2026: actual —, estimate 21.04M USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$84.86

0.09% upside
Past 12 months12-month forecastHigh $85.00Average $84.86Low $84.00

Rating distribution

21 ratings
Strong buy00%
Buy1362%
Hold838%
Sell00%
Strong sell00%

Recent analyst actions

12 institutions
UBSdowngradeBuyNeutral
TD CowendowngradeBuyHold
Jones TradingdowngradeBuyHold

CRNX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$443.84

+1.03%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.74

+0.42%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.59

-0.08%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$373.57

-1.38%

Sanofi logo

SNY

Sanofi

$45.69

-0.35%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$828.5

-0.66%

ETFs holding CRNX

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
280.14M
Weight
0.01%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$377.07-0.31%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
222.16M
Weight
0.27%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$297.97-0.66%
Vanguard Morningstar Small-Cap ETF logoVanguard Morningstar Small-Cap ETFVB
Market value
202.49M
Weight
0.11%
AUM
183.4B USD
Expense ratio
0.03%
Price / 1D
$302.9-0.61%
Vanguard Morningstar Small-Cap Growth ETF logoVanguard Morningstar Small-Cap Growth ETFVBK
Market value
117.19M
Weight
0.26%
AUM
43.8B USD
Expense ratio
0.05%
Price / 1D
$354.85-1.06%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
101.41M
Weight
0.11%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.43-0.86%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
81.5M
Weight
0.54%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$383.16-1.09%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
61.57M
Weight
0.58%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$212.53-0.48%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
48.61M
Weight
0.27%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.47-0.64%

Continue in GoAI

Research CRNX

research.disclaimer